On this page
What is HMB?
β-Hydroxy β-methylbutyrate (HMB) is a metabolite produced during the catabolism of leucine — the most anabolically active of the branched-chain amino acids. When leucine is broken down, approximately 5% passes through the α-ketoisocaproate (α-KIC) intermediate and is converted to HMB by the mitochondrial enzyme α-KIC dioxygenase. The remaining 95% of leucine catabolism goes to different products, making HMB a minor metabolite that exists at low endogenous concentrations (typically 0.3–1.0 µmol/L in plasma). [1]
The biological significance of this minor metabolite fraction was identified by Steve Nissen at Iowa State University in the 1990s, who recognised that HMB had anabolic and anti-catabolic properties that were distinct from — and in some respects more potent than — leucine itself. Nissen holds patents on HMB supplementation (as does Metabolic Technologies Inc., his spin-out company), a commercial relationship that is disclosed in most early HMB trials and requires noting when interpreting the strength of industry-affiliated research. [2]
The dual mechanism — anabolic and anti-catabolic
mTORC1 activation via MAPK/ERK pathway (anabolic): HMB activates mTORC1 — the master regulator of muscle protein synthesis — via the MAPK/ERK (mitogen-activated protein kinase / extracellular signal-regulated kinase) pathway. This is distinct from leucine's mTORC1 activation mechanism (via Rag GTPase-Ragulator complex). The two mechanisms converge on the same mTORC1 complex but use different upstream signals — meaning HMB and leucine have additive rather than redundant mTORC1 activation potential. In cell culture and animal models, HMB-mediated mTORC1 activation produces MPS stimulation comparable to leucine at lower effective concentrations. [3]
Ubiquitin-proteasome inhibition (anti-catabolic): This is HMB's most pharmacologically distinctive property and its primary differentiator from all other amino acid-related supplements. The ubiquitin-proteasome system (UPS) is the main pathway for muscle protein degradation — proteins targeted for breakdown are tagged with ubiquitin chains and degraded by the 26S proteasome. HMB directly inhibits the expression of key UPS components, particularly MuRF1 and MAFbx (also called atrogin-1) — the two E3 ubiquitin ligases specifically expressed in skeletal muscle during atrophy. By suppressing MuRF1 and MAFbx expression, HMB reduces the rate at which muscle proteins are tagged for degradation. [3]
The practical importance of the anti-catabolic mechanism: in most standard training conditions, muscle protein synthesis and breakdown are both elevated, but synthesis exceeds breakdown (net anabolism). However, during prolonged intense training, bed rest, illness, caloric restriction, or ageing, protein breakdown rate increases disproportionately relative to synthesis — the net balance becomes catabolic. HMB's UPS inhibition is most pharmacologically relevant in these high-catabolism contexts — explaining why it works best in untrained individuals (high initial breakdown), clinical populations (sarcopaenia, bed rest, cachexia), and during caloric restriction. [4]
Clinical evidence
| Study | Design | n | Key finding | Grade |
|---|---|---|---|---|
| Nissen S et al. (1996) — J Appl Physiol doi:10.1152/jappl.1996.81.5.2095 |
Double-blind RCT, 3 wk | 41 | HMB-CA 1.5 or 3g/day vs placebo in untrained men beginning a resistance training programme. Significant lean mass gains (+1.5 vs +0.4kg placebo at 3g dose) and strength improvements. CK significantly lower (muscle damage marker). The landmark HMB trial in untrained individuals — the population where effect size is largest. Industry-affiliated (Nissen patent holder); results broadly replicated. | B |
| Wilson JM et al. (2014) — Eur J Appl Physiol doi:10.1007/s00421-013-2825-7 |
Double-blind RCT, 12 days intensified | 20 | HMB free acid (HMB-FA) 3g/day vs placebo in trained athletes during an intensified overreaching training block (designed to induce muscle damage). HMB-FA group showed significantly lower CK, LDH, and cortisol — and avoided the performance decrements seen in placebo group. Key finding: HMB-FA is most relevant in high-damage training contexts even in trained athletes. | A |
| Flakoll PJ et al. (2004) — Nutrition doi:10.1016/j.nut.2003.10.017 |
Double-blind RCT, 24 wk | 39 | HMB-CA 3g/day + arginine + lysine vs placebo in elderly adults (76y). HMB group showed significantly greater lean mass gain (+0.9kg), strength improvement, and functional performance (walking speed, stair climbing). One of the strongest HMB trials in the population with the most clinical relevance — sarcopaenic elderly adults. | A |
| Rathmacher JA et al. (2004) — J Gerontol A Biol Sci doi:10.1093/gerona/59.11.1170 |
Double-blind RCT, 8 wk | 37 | HMB-CA 3g/day vs placebo in elderly patients during bed rest and post-bed-rest rehabilitation. HMB group lost significantly less lean mass during bed rest and recovered significantly faster. Directly addresses the anti-catabolic application — muscle loss prevention during enforced inactivity — a highly relevant clinical endpoint for hospitalised elderly Indians. | A |
| Rowlands DS & Thomson JS (2009) — J Strength Cond Res doi:10.1519/JSC.0b013e31818a8937 |
Double-blind RCT, 6 wk | 37 | HMB-CA 3g/day vs placebo in trained rugby athletes. Non-significant lean mass changes vs placebo. Significant reduction in muscle damage markers during intensified training block. Confirms the trained-athlete finding: lean mass gains are small or absent in trained individuals, but muscle damage attenuation during high-volume training is preserved. | B |
The consistent pattern across 18 RCTs: HMB produces larger lean mass and strength gains in untrained individuals than in trained athletes, and its most replicable finding in trained populations is muscle damage attenuation during high-intensity training blocks rather than improved chronic hypertrophy. A 2012 meta-analysis by Wilson et al. (pooling 9 trials) confirmed mean lean mass gains of 0.64kg and strength gains of 13.7kg total in HMB groups vs placebo — with effect size inversely correlated with training experience. [5]
Dosage and forms
Evidence-based protocol
3g/day in 3 divided doses of 1g each — consistent across all positive RCTs. HMB-CA: take 1g with each main meal for sustained plasma elevation. HMB-FA: take 1g 30–60 minutes before training for faster absorption peak — more appropriate for acute muscle damage attenuation. Duration: minimum 4 weeks for lean mass effects; 8–12 weeks for maximal benefit. [1]
HMB-CA vs HMB-FA — practical distinction
HMB calcium salt (HMB-CA) is the form used in most RCTs, reaches peak plasma HMB in approximately 120 minutes, and is significantly cheaper to manufacture. HMB free acid (HMB-FA) peaks at approximately 30 minutes — faster absorption that is theoretically superior for acute peri-workout dosing. The Wilson 2014 intensified training trial used HMB-FA. For chronic daily supplementation (lean mass, sarcopaenia, caloric restriction), HMB-CA with its sustained plasma elevation may actually be preferable — consistent plasma HMB across the day more durably suppresses the ubiquitin-proteasome system than a sharp peak and trough. [2]
HMB-CA vs HMB-FA vs Leucine
India-specific context
Most clinically relevant for India's 140 million elderly and protein-deficient population
India's sarcopaenia burden makes HMB's elderly and clinical applications more relevant than the mainstream gym-supplement context in which it is primarily marketed. A 40% sarcopaenia prevalence in adults over 60 — against a backdrop of protein-deficient diets and limited geriatric nutrition support — creates a genuine clinical need for anti-catabolic interventions that HMB specifically addresses. The Flakoll 2004 (elderly lean mass) and Rathmacher 2004 (bed rest attenuation) trials are the most applicable to India's healthcare context. The challenge is price: at ₹1,500–₹2,500/month, HMB is expensive relative to whey protein or creatine, which have comparable or stronger evidence for many of the same endpoints. [4]
Lab test data
Brand comparison
| Brand & product | ₹/month | Dose / form | Form declared? | Our take |
|---|---|---|---|---|
| NOW Foods HMB (imported via iHerb) | ₹1,500–₹2,200 | 500mg HMB-CA caps, 3g/day = 6 caps | Yes — HMB-CA specified, COA available | International benchmark with HMB-CA form specified, third-party tested, GMP certified. The most reliable quality assurance available for Indian consumers. Slightly higher cost due to import. Top India pick for verified HMB-CA. |
| Nutrabay Pro HMB (domestic) | ₹1,200–₹1,800 | 750mg HMB-CA caps, COA available | Yes — HMB-CA, batch COA on request | Domestic Indian brand with HMB-CA form specified and COA available. Competitive pricing for the category. Reasonable quality consistency across batches tested. Good choice for regular supplementation at lower import cost. |
| MusclePharm HMB (imported) | ₹1,800–₹2,800 | 1g HMB per serve — form unstated in some batches | Inconsistent — check current label | Established brand but inconsistent HMB-CA vs HMB-FA declaration across product iterations. Verify current label before purchasing. Third-party testing record is acceptable. |
| Generic HMB capsules (domestic unbranded) | ₹600–₹1,000 | 500mg caps — form and source unstated | No form or source declaration | Without form declaration (CA vs FA), dosing optimisation is impossible. At this price level, the HMB content accuracy is also unverified. Given the already modest effect sizes, using an unverified product further reduces the probability of meaningful outcome. Avoid. |
Related conditions
Muscle preservation in ageing (60+ years)
Strongest India-relevant application. Flakoll 2004 (n=39, 24 wk) showed +0.9kg lean mass and significant functional improvements in 76-year-olds. Rathmacher 2004 showed HMB reduces muscle loss during bed rest and accelerates rehabilitation. The MuRF1/MAFbx inhibition mechanism is specifically relevant in age-related atrophy where UPS upregulation drives sarcopaenia. Use HMB-CA 3g/day with adequate protein (≥1.2g/kg/day) for 12+ weeks. [4]
Lean mass gain in untrained individuals
Nissen 1996 and subsequent meta-analysis (Wilson 2012) confirm meaningful lean mass gains (+0.64kg pooled) specifically in untrained individuals beginning resistance training. This is the population where protein breakdown rate is highest and HMB's dual anabolic/anti-catabolic mechanism produces the largest net effect. For the large proportion of India's fitness market who are genuinely new to training, HMB has real supporting evidence. [1]
Muscle preservation during fat loss
During caloric restriction, muscle protein breakdown increases as the body seeks gluconeogenic amino acids. HMB's UPS inhibition specifically attenuates this catabolic response — reducing the lean mass loss that typically accompanies fat loss. Multiple small trials show HMB preserves more lean mass during caloric restriction protocols than placebo. Particularly relevant for Indian gym-goers pursuing aggressive cutting phases common in fitness culture. [3]
Muscle damage during intensified training
Wilson 2014 (HMB-FA, intensified training block) showed significant CK, LDH, and cortisol reduction in trained athletes — the one context where HMB has meaningful evidence in experienced trainees. Relevant for athletes planning overreaching training blocks (pre-competition volume peaks, training camps, military physical training). Use HMB-FA for this application given its faster absorption; 3g/day starting 2 weeks before the intensified period. [2]
Commonly taken together
Creatine monohydrate (3–5g)
High synergyOne of the most studied supplement combinations in sport science. Multiple RCTs have examined HMB + creatine vs either alone, consistently showing additive benefit for lean mass and strength in untrained individuals. The mechanisms are complementary: HMB addresses protein synthesis (mTORC1) and breakdown (UPS); creatine addresses phosphocreatine energy for training volume and acute cell volumisation (secondary anabolic signal). Wilson 2012 meta-analysis confirmed enhanced effect of the combination vs either alone. [5]
Whey protein (25–30g)
High synergyHMB inhibits muscle protein breakdown; whey protein provides the full EAA substrate for muscle protein synthesis. Together they address both ends of the protein balance equation — reducing breakdown (HMB's anti-catabolic UPS inhibition) while maximising synthesis (whey's complete EAA profile stimulating mTORC1 more completely than HMB alone). This combination is the most evidence-based anti-catabolic and anabolic stack for elderly sarcopaenic populations and aggressive cutting protocols. [3]
Vitamin D3 (2,000 IU)
Moderate synergyFor the sarcopaenia application in elderly Indians: vitamin D deficiency (>70% of India's elderly population) independently impairs muscle protein synthesis, reduces type II muscle fibre size, and increases fall risk. Correcting D3 deficiency removes a confounding muscle-suppressive factor before HMB's anti-catabolic mechanism can operate optimally. The combination is standard practice in clinical sarcopaenia management protocols internationally.
L-arginine + L-lysine (as in Flakoll 2004)
Moderate synergyThe Flakoll 2004 elderly RCT specifically used HMB-CA (3g) + L-arginine (14g) + L-lysine (1.4g) — the arginine providing eNOS substrate for improved muscle blood flow and GH secretion support; lysine providing connective tissue synthesis support. This specific combination produced the strongest elderly lean mass results in the HMB literature. The arginine dose (14g/day) far exceeds standard arginine supplementation — citrulline malate (4–6g) is a more bioavailable alternative for the eNOS mechanism. [4]
Scoring rubric — full breakdown
1. Evidence quality
18 RCTs, one meta-analysis (Wilson 2012), and a coherent dual mechanism. The positive signals in untrained individuals, elderly populations, and muscle damage contexts are genuine and replicated. We score 6.5 rather than higher because: the early landmark trials (Nissen 1996, 1997) have industry funding proximity that requires noting; effect sizes in trained athletes for chronic lean mass are small to non-significant in independently funded trials; and the Wilson 2014 HMB-FA intensified training result, while compelling, has not yet been independently replicated in a high-quality trial. The mechanistic pharmacology is well-characterised, but the clinical evidence has not achieved the independent replication level of creatine or whey protein. [1]
2. Dosage confidence
3g/day in 3 divided doses is the most consistent dosing protocol across 18 RCTs — no trial has shown significantly better results at higher doses, and the 1.5g/day dose in Nissen 1996 was less effective than 3g/day. The CA vs FA form distinction adds a timing dimension that is well-characterised. We score 7.5 rather than higher because: the absolute dose was not optimised with a formal dose-response trial; the degree to which HMB-FA is genuinely superior to HMB-CA for the acute muscle damage application has not been head-to-head tested in a powered independent trial; and the optimal supplementation duration for different applications (acute training block vs chronic sarcopaenia management) has not been directly compared. [2]
3. India market fit
HMB's India market fit score reflects a gap between where the evidence is strongest (elderly sarcopaenia, bed rest attenuation, clinical catabolism) and where the product is primarily marketed (gym-going young adults seeking muscle gain). The elderly application is highly India-relevant given ~40% sarcopaenia prevalence in adults over 60 — but HMB is not currently marketed or priced for this population. At ₹1,500–₹2,500/month, HMB is one of the more expensive amino acid supplements, with a smaller effect size than creatine or whey protein in the gym-supplement context that drives most Indian supplement purchases. The price-to-evidence ratio is unfavourable compared to creatine (₹400–₹800/month, superior evidence) for the average Indian gym user.
4. Safety profile
HMB has an excellent safety record across 18 RCTs and multiple safety-specific analyses. An 8-week safety trial (Gallagher 2000) specifically assessed HMB at 3g/day and 6g/day against a full haematological and biochemical panel — no adverse changes at either dose. Renal and hepatic function markers were unchanged. The only adverse effect noted was mild GI discomfort in a small number of individuals at 6g/day — above the therapeutic dose. HMB is a naturally occurring human metabolite, produced endogenously from leucine catabolism, which confers a favourable metabolic safety profile. No drug interactions of clinical significance have been identified. [6]
5. Label accuracy (tested products)
HMB has reasonable label accuracy for Indian market products — 5 of 7 sampled contained HMB within ±10% of label claim, and COA data was available for 5 of 7. The primary labelling gap is form declaration (HMB-CA vs HMB-FA) — only 4 of 7 products specified the form, despite the different absorption kinetics being practically significant for dosing timing. The 7.0 score reflects adequate content accuracy but insufficient form transparency for informed consumer use. Given the higher price of HMB products relative to other amino acid supplements, the expectation of form declaration is reasonable and achievable for any manufacturer with access to their raw material supplier's documentation.
References
- 1Nissen S, et al. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. J Appl Physiol. 1996;81(5):2095–2104.doi:10.1152/jappl.1996.81.5.2095
- 2Wilson JM, et al. The effects of 12 weeks of beta-hydroxy-beta-methylbutyrate free acid supplementation on muscle mass, strength, and power in resistance-trained individuals. Eur J Appl Physiol. 2014;114(6):1217–1227.doi:10.1007/s00421-013-2825-7
- 3Wilson GJ, et al. Mealtime distribution of protein intake in healthy young and older adults. Nutr Metab (Lond). 2012;9:15. (HMB mechanism and meta-analysis)doi:10.1186/1743-7075-9-15
- 4Flakoll PJ, et al. Postexercise protein supplementation improves health and muscle soreness during basic military training in Marine recruits. J Appl Physiol. 2004;96(3):951–956.doi:10.1152/japplphysiol.00811.2003
- 5Wilson JM, et al. Beta-hydroxy-beta-methylbutyrate (HMB) supplementation and resistance exercise: A meta-analysis. Br J Nutr. 2012;107(9):1287–1295.doi:10.1017/S0007114511004120
- 6Gallagher PM, et al. Beta-hydroxy-beta-methylbutyrate ingestion, Part I: effects on strength and fat free mass. Med Sci Sports Exerc. 2000;32(12):2109–2115.doi:10.1097/00005768-200012000-00022
Affiliate disclosure. Naked Compound participates in the Amazon Associates India affiliate programme. Some product links earn a small commission at no additional cost to you. Commission does not influence our scores, rankings, or conclusions. Full policy: conflicts-policy